Atricure Stock Price, News & Analysis

AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter of 2022 with revenues reaching $84.5 million, a growth of 18.4% compared to the previous year. U.S. sales rose by 18.6% to $71.3 million, driven by significant demand for products like the cryoSPHERE® probe and AtriClip® devices. However, the company recorded a loss from operations of $13.7 million with an adjusted EBITDA loss of $3.2 million. For 2022, AtriCure anticipates revenues between $323 million and $333 million, reflecting 18% to 21% growth over 2021.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib) and related conditions, has announced participation in two investor conferences. The management will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 10:00 a.m. ET. Additionally, they will engage in meetings at the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 15, 2022. AtriCure is known for its innovative technologies, including the first FDA-approved device for persistent Afib treatment and widely used devices for left atrial appendage management.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will release its second quarter 2022 financial results on August 2, 2022. An audio webcast will be held at 4:30 p.m. Eastern Time to discuss these results, accessible via AtriCure's investor page. The Isolator® Synergy™ Ablation System, the first FDA-approved device for persistent Afib, and the widely used AtriClip® devices showcase the company's innovation in Afib management. With over 33 million Afib patients globally, AtriCure continues to address related healthcare challenges.

AtriCure announced the initiation of the HEAL-IST trial, the first patient was treated at University Hospital Brussels. This trial will assess the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp for patients with Inappropriate Sinus Tachycardia, a condition that affects young adults with limited treatment options. The trial will involve 142 patients across 40 centers in the U.S. and Europe, focusing on achieving a heart rate of less than 90 bpm. The study aims to establish a new standard of care for this condition.

AtriCure, Inc. has appointed Deborah Yount as the new Chief Human Resources Officer, effective immediately. Yount joins from Medtronic, where she was Vice President of Global Human Resources for the Cardiovascular sector, significantly impacting over $10 billion in annual revenue. CEO Michael Carrel expressed enthusiasm about Yount's extensive experience in human capital management, anticipating strong growth opportunities in addressing the Afib epidemic and improving post-operative pain management.

AtriCure, Inc. (Nasdaq: ATRC) reported its first quarter 2022 financial results, showcasing a 25.8% revenue increase to $74.6 million compared to Q1 2021. U.S. revenue rose by 23.8% to $62.3 million, driven by strong sales in cryoSPHERE® probes and AtriClip® Flex-V devices. International revenue also surged by 37.2% to $12.3 million. Despite a net loss of $14.2 million, the company maintains a positive outlook with projected full-year revenue of $318 million to $330 million, anticipating 16% to 20% growth for 2022.

AtriCure, Inc. (NASDAQ: ATRC) has launched the EnCompass Clamp^® as part of its Isolator Synergy™ Ablation System in the U.S. The clamp received FDA 510(k) clearance for cardiac tissue ablation during surgery, enhancing efficiency in concomitant ablation procedures. Key features include parallel closure, uniform pressure, and a magnetic guide for easier placement. CEO Michael Carrel highlighted its innovative design to improve surgical outcomes, while Dr. Prem Samuel praised its efficiency in minimizing tissue dissection and achieving effective results in a single maneuver.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its upcoming release of first-quarter financial results on May 3, 2022, at 4:30 PM ET. Investors can join a conference call or access a live audio webcast via the company's website. AtriCure's innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and the widely used AtriClip® Left Atrial Appendage Exclusion System, support efficient Afib treatment, impacting millions globally. For more information, visit AtriCure.com.

AtriCure, Inc. (Nasdaq: ATRC) reported strong financial results for Q4 and full-year 2021. Q4 revenue reached $73.2 million, up 26.8% from 2020, driven by U.S. sales of key products. Full-year revenue was $274.3 million, a 32.8% increase. Gross profit for 2021 was $205.9 million, while the gross margin improved to 75%. However, the company faced a loss from operations of $12.5 million in Q4 and anticipates an adjusted EBITDA loss in 2022. The 2022 revenue forecast ranges from $315 million to $330 million, reflecting growth of 15% to 20%.